Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Annexon, Inc.ANNX · Entity 5011 | Director | June 02, 2021 | June 04, 2021 |
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 09, 2021 | June 11, 2021 |
| Savara IncSVRA · Entity 4900 | Director | December 14, 2023 | December 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Annexon, Inc.
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.03 · Expires 2031-06-02 | Direct | 10,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 10,000 · Balance 10,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date.
Arcutis Biotherapeutics, Inc.
Report date June 09, 2021 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.77 · Expires 2031-06-09 | Direct | 13,391 |
Reported balance
After 2021-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-09 · Grant · Acquired 13,391 · Balance 13,391 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date.
Savara Inc
Report date December 14, 2023 · Filed December 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,500 |
Reported balance
After 2023-12-14 transaction · row 1
1 source rowRow 1 · 2023-12-14 · Grant · Acquired 22,500 · Balance 22,500 F1: Represents restricted stock units ("RSUs") that vest in full on December 14, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that vest in full on December 14, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2023 Filed Dec 15, 2023 23:10 UTC | Savara Inc SVRA · Entity 4900 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-070862 · ownership.xml · nonDerivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 F1 · shares: Represents restricted stock units ("RSUs") that vest in full on December 14, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:13 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000899243-22-038597 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-12-13 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable on December 13, 2023. Read SEC document |
| December 14, 2021 Filed Dec 15, 2021 23:30 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0000899243-21-048398 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-12-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable on December 14, 2022. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:30 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 13,391 | $0.00 Strike: $27.77 | $0.00 |
DisclosureSEC source: 0000899243-21-023301 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Underlying: Common Stock · 13,391 shares Expires 2031-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:00 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-21-022064 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 01:15 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0000899243-20-034330 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable on December 16, 2021. Read SEC document |
| March 10, 2020 Filed Mar 17, 2020 21:43 UTC | Savara Inc SVRA · Entity 4900 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0000899243-20-008648 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: The shares subject to the option vest quarterly over 3 years from Dr. Sun's appointment as a director of the Issuer, subject to Dr. Sun's continued service with the Issuer. Read SEC document |
| February 27, 2020 Filed Mar 4, 2020 21:42 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $27.61 | $0.00 |
DisclosureSEC source: 0000899243-20-006958 · doc4.xml · derivative · entry 1 Sun Ricky · CIK 0001790589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.